Outset Medical, Inc. (OM)
NASDAQ:OM
Want to see OM full AI Analyst Report?
OM Stock Chart & Stats
$4.35
-$0.10(-9.09%)
At close: 4:00 PM EST
$4.35
-$0.10(-9.09%)
Day’s Range― - ―
52-Week Range$3.00 - $21.36
Previous CloseN/A
Volume1.92M
Average Volume (3M)191.33K
Market Cap
$79.80M
Enterprise Value$152.80M
Total Cash (Recent Filing)$156.71M
Total Debt (Recent Filing)$4.68M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Aug 05, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.16
Shares Outstanding18,537,241
10 Day Avg. Volume182,336
30 Day Avg. Volume191,327
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap1.91
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit3.20
Enterprise Value/Ebitda-2.45
Forecast
1Y Price Target
$7.67Price Target Upside76.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.86
Revenue Forecast (FY)$126.77M
Bulls Say, Bears Say
Bulls Say
High Recurring Revenue MixConsumables and service representing roughly 70% of revenue create predictable, high‑frequency cash flows tied to treatments. This installed‑base pull‑through reduces reliance on capital sales, supports steady revenue and margin resilience even if machine placements are lumpy.
Material Gross Margin ImprovementSustained gross margin expansion (620 bps YoY) and strong product margins show improving unit economics and pricing or cost structure gains. Higher margins support a clearer path to profitability and lower cash burn as revenue scales, a durable fundamental improvement.
Strong Balance Sheet FlexibilityLow leverage and a sizable equity base provide runway and reduce refinancing risk, enabling investments in commercialization and next‑gen rollout without immediate capital raises. This financial flexibility supports execution over the next several quarters.
Bears Say
Deep Ongoing Losses & Negative FCFDespite margin gains, the company remains deeply unprofitable with materially negative free cash flow. Persistent operating losses strain capital over time and raise the prospect of dilution or additional financing if revenue growth stalls, a structural risk to long‑term stability.
Revenue Decline & Capital Order LumpinessQuarterly declines and volatile capital sales underline dependence on timing of large orders. Back‑half loaded guidance increases execution risk: if expected orders or deployments slip, recurring revenue growth and cash generation will lag, undermining the path to breakeven.
Dependence On Next‑gen Tableau RolloutManagement's growth thesis depends on the next‑generation Tableau (positioned on new cybersecurity rules) to drive placements and consumables pull‑through. Any delays, weaker adoption, or integration issues would materially impair expected revenue uplift and margin upside.
Outset Medical News
OM FAQ
What was Outset Medical, Inc.’s price range in the past 12 months?
Outset Medical, Inc. lowest stock price was $3.00 and its highest was $21.36 in the past 12 months.
What is Outset Medical, Inc.’s market cap?
Outset Medical, Inc.’s market cap is $79.80M.
When is Outset Medical, Inc.’s upcoming earnings report date?
Outset Medical, Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 49 days.
How were Outset Medical, Inc.’s earnings last quarter?
Outset Medical, Inc. released its earnings results on May 07, 2026. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.79 by -$0.04.
Is Outset Medical, Inc. overvalued?
According to Wall Street analysts Outset Medical, Inc.’s price is currently Undervalued.
Does Outset Medical, Inc. pay dividends?
Outset Medical, Inc. does not currently pay dividends.
What is Outset Medical, Inc.’s EPS estimate?
Outset Medical, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Outset Medical, Inc. have?
Outset Medical, Inc. has 18,537,241 shares outstanding.
What happened to Outset Medical, Inc.’s price movement after its last earnings report?
Outset Medical, Inc. reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.79. Following the earnings report the stock price went down -21.047%.
Which hedge fund is a major shareholder of Outset Medical, Inc.?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.67 (76.25% Upside)
$7.67 (76.25% Upside)
Blogger Sentiment
Bullish
OM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.40%
12-Months-Change
Fundamentals
Return on Equity
-55.88%
Trailing 12-Months
Asset Growth
-17.18%
Trailing 12-Months
Company Description
Outset Medical, Inc.
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
OM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial trajectory: substantial gross margin expansion (620 bps), a 32% improvement in non-GAAP net loss, strong cash balance ($161M) with lower-than-expected cash burn, and a strategic next-generation product and experienced commercial hire poised to drive future demand. Offsetting these positives were a 6% year-over-year revenue decline in Q1 driven by lumpiness in capital orders (product revenue down 13%), modestly higher operating expenses, and reliance on the timing and success of the next-gen Tableau launch to deliver back-half revenue. On balance, the positive margin, cash, and operational execution updates outweigh the timing-related revenue headwinds.View all OM earnings summariesOM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$7.67
▲(76.25% Upside)
Technical Analysis
Ownership Overview
18.02% Insiders
22.24% Mutual Funds
24.03% Other Institutional Investors
26.61% Public Companies and
Individual Investors